Login to Your Account


Antibody-Drug Conjugate Development

ImmunoGen Signs $220M TAP Deal with Eli Lilly

By Catherine Shaffer
BioWorld Today Contributing Writer

Wednesday, December 21, 2011

ImmunoGen Inc. licensed its maytansinoid targeted antibody payload (TAP) technology to Eli Lilly and Co., for the development of a limited number of antibody-drug conjugates for cancer. Lilly will pay $20 million up front and up to $200 million in milestone payments. ImmunoGen will also receive compensation for any research and manufacturing services it may provide to Lilly.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
 
For Sales Inquiries:
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
 
Privacy Policy | Terms of Use
 
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
bioworld.support@thomsonreuters.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
© 2013 Thomson Reuters. Reproduction, reposting content is strictly prohibited.

Free Ezine

Sign up for Perspectives FREE e-mail newsletter

Click here